MESOBLAST LTD (MESO) Form 6-K — Jun 10, 2026
Mesoblast reported that its approved product Ryoncil has generated over US$100 million in net revenue since its US launch last year, demonstrating successful commercial traction for its allogeneic stem cell therapy. The company highlighted strong profitability, with Q3 FY26 net revenue of US$30.3 million and a gross profit of US$44.2 million in the first half of FY26, allowing it to reduce net operating cash spend to just US$4.1 million in Q3.
Key figures
- Revenue
- 30300000
- Cash Position
- 122000000
- Gross Proceeds
- 125000000
- Direct selling costs
- 7700000
- Q3 fy26 gross revenue
- 35300000
- Ryoncil gross profit 1h fy26
- 44200000
- Ryoncil cumulative net revenue
- 100000000
- Net operating cash spend q3 fy26
- 4100000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.